Published : 27 Feb 2019, 10:51 PM
Updated : 21 Jun 2022, 08:21 PM
Diabetes is a chronic condition that occurs when the body cannot produce enough insulin or effectively. Insulin is a hormone produced by the pancreas that allows glucose from food to enter the body's cells where it is converted into energy needed by muscles and tissues to function. As a result a person with diabetes does not absorb glucose properly, and glucose keeps circulating in the blood (hyperglycaemia), damaging tissue over time. This damage leads to life-threatening health complications.
The Bangladesh Diabetic Samity (BADAS) or Diabetic Association of Bangladesh was established on Feb 28, 1956 through the initiative of the late National Professor Dr M Ibrahim (1911-1989). Its declared motto is to look after all people with diabetes irrespective of their ability to pay, status or other factors. BADAS has developed several institutions and projects and inspired a large number of affiliated associations all over the country to help fulfil the mission. BADAS, which is turning 63 this year, is self-reliant and not dependent on donors. BADAS is the pioneer, model and first success story of Public Private Partnership (PPP) development in Bangladesh, and has developed infrastructure through partnerships with the government. BADAS provides services to the affluent and to people who don't have diabetes and through a policy of cross-financing; it then helps others living with diabetes with the surplus capital that it generates.
BIRDEM (Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders) is the central institute of BADAS which provides comprehensive diabetic healthcare to the people. It is a unique creation of the BADAS and has been acclaimed as a model institution in Asia and the Pacific. The institute has 650 in-patient beds and a large out-patient program. BIRDEM has about 0.5 million registered diabetic patients, more than 4,000 people visit every day here and out of these patients 75-100 are new. After a review of the influx of patients treated everyday, BIRDEM has been adjudged as a unique and successful health service provider across the globe.
BADAS adopted a decentralised model and has spread care throughout the country. There are 61 affiliates, almost one in every district, and 10 sub-affiliated associations at the Upazila level in Bangladesh. They have to follow certain standards – they must be democratic, transparent, must be run by social workers, and must be non-profits. Through this BADAS has been able to create comparatively excellent diabetes awareness. Bangladesh is a developing country, but in terms of awareness of diabetes it is far ahead of some developed countries. Here people in general are aware of the need to act to soften the possible impact of the diabetes epidemic.
According to Eighth Edition of Diabetes Atlas (2018) published by the International Diabetic Federation, the estimated number of adults living with diabetes has soared to 374 million, representing 8.4 percent of the global adult population. This number is projected to increase to 552 million people by 2030, or 9.9 percent of adults, which equates to approximately three more people with diabetes every 10 seconds. None can deny the crude fact that diabetes imposes a large economic burden on any national healthcare system. Estimated figures show healthcare expenditures on diabetes accounted for 11.6 percent of the total healthcare expenditure in the world in 2010. About 95 percent of countries spend 5 percent or more of their total healthcare dollars on diabetes. IDF estimates also project that global health expenditures to prevent and treat diabetes and its complications surpassed $376 billion in 2010 and by 2030, this number will exceed some $490 billion. An average of $703 per person was depleted on diabetes in 2010 globally. More than three-quarters of the global expenditure in 2014 was used for persons who are between 50 and 80 years of age. Also, more money is expected to be spent on diabetes care for women than for men.
Research results show that there remains a large disparity in healthcare spending on diabetes between regions and countries. More than 80 percent of the global expenditures on diabetes are made in the world's economically richest countries, not in the low- and middle-income countries where 80 percent of people with diabetes live. Recent studies drew three major conclusions on the overall economic impact of diabetes
First, diabetes imposes a large financial burden on people with diabetes and their families. The size of this burden depends on their economic status and the social insurance policies of the countries in which they live. Individuals with diabetes and their families in developing countries pay a larger share of the expenditure because of the poorer organised systems of medical care insurance and/or lack of governmental provision of medical services. In the poorest countries, people with diabetes and their families bear almost the whole cost of whatever medical care they can afford. In Bangladesh, exceptionally, clinical cum social services (a certain percentage of free services) are offered to diabetes patient through chain hospitals and healthcare centres of the Diabetic Association. In India, the poorest persons with diabetes spend an average of 25 percent of their total income on healthcare.
Second, at the societal level, diabetes leads to loss in productivity and economic growth. The American Diabetes Association estimated that the US economy lost $58 billion, equivalent to about an half of the direct health care expenditure on diabetes in 2007, as a result of lost earnings due to lost work days, restricted activity days, lower productivity at work, mortality and permanent disability caused by diabetes. Such losses are found relatively larger in poorer countries because premature death due to diabetes occurs at much younger ages. The World Health Organization (WHO) predicts net losses in national income from diabetes and cardiovascular disease of $557.7 billion in China, $303.2 billion in the Russian Federation, $336.6 billion in India, $49.2 billion in Brazil and $2.5 billion in Tanzania (2005 ID), between 2005 and 2015.
Finally, the largest economic burden caused by diabetes is the monetary value associated with disability and loss of life as a result of the disease itself and its related complications including heart, kidney, eye and foot disease. Economists have used different methods to value disability and loss of life associated with diseases and the most appropriate method is still under debate. No matter what method is used, it is very likely the economic burden that is measured by the monetary value associated with this disability and loss of life would be far larger than the estimated economic burden using measures described above.
Most people with diabetes live in the economically less developed regions of the world. Even in the region with the lowest prevalence (Africa) it is estimated that around 280,000 deaths were attributable to diabetes in 2011. While more than 80 percent of people with diabetes live in low and middle-income countries only 20 percent of global healthcare expenditures on diabetes were spent in these countries, reflecting huge disparities.
Diabetes is reaching epidemic proportions worldwide. Every year more people are diagnosed with diabetes, yet there are still many (more than 50 percent) people who have diabetes and do not know it. In a small survey it is indicated that the prevalence of diabetes in Bangladesh in populations aged over 15 years is between 2 percent to 5 percent. This is similar to the level found in most the under-developed countries.
Diabetes is a life-long and non-episodic disease. It affects many other organs of the body. So a comprehensive and proper pathological support-based treatment is needed to manage it. Self-management of the patient is also an important phenomenon in diabetes management. At the same time record-keeping, health education to the patient and their community is also needed.